In another study by Dehdashti et al., they demonstrated that the estradiol-challenge test using FFNP-PET effectively predicts response to endocrine therapy (ET) in advanced ER+ breast cancer patients, with a >6.7% increase in FFNP uptake accurately identifying responders, with 100% PPV and NPV. Here, ESR1 is linked to breast carcinoma.